Status:

COMPLETED

Safety Study of P28GST Treatment in Crohn's Disease Patients

Lead Sponsor:

University Hospital, Lille

Collaborating Sponsors:

National Research Agency, France

Institut National de la Santé Et de la Recherche Médicale, France

Conditions:

Crohn's Ileocolitis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This multicenter phase 2 clinical trial is designed to assess safety of P28GST (protein 28 Kd glutathion S Transferrase), aiming to control inflammation in moderate Crohn's Disease (CD), before or aft...

Detailed Description

To carry out this study, 24 moderate CD patients will be enrolled in a safety phase 2a study. CD patients will be included after intestinal resection surgery or in moderate Crohn's Disease (CD). Drug ...

Eligibility Criteria

Inclusion

  • Subjects between the ages of ≥18 years at inclusion.
  • Subjects with ileal or ileo-colic CD without fistula
  • Subjects operated or not
  • CDAI score \< 220
  • no concomitant treatment excepted salicylates
  • Women of child bearing potential must be negative for pregnancy prior to study enrolment
  • contraceptive means : females of childbearing potential as well as males are required to use adequate contraceptive methods for 6 months starting at the inclusion, i;e 4 months after the 3rd injection .
  • No tobacco consumption (end date of tobacco consumption 8 days before surgery).
  • Signed consent form
  • French social security coverage.

Exclusion

  • Subject who use of azathioprine, anti-TNF (Tumor Necrosis Factor), methotrexate, Vedolizumab, Ustekinumab and other immunosuppressors for 8 weeks before first injection of P28GST
  • Subject who use of corticosteroids for 15 days before first injection of P28GST
  • Subject with history of vaccine hyper sensitivity or allergy.
  • Subject with any other clinical manifestation determined by the investigator
  • Subject wih AIDS, B or C hepatitis.

Key Trial Info

Start Date :

March 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2018

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT02281916

Start Date

March 1 2014

End Date

February 1 2018

Last Update

December 22 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Centre hospitalier

Amiens, France

2

Centre Hospitalier de Boulogne

Boulogne-sur-Mer, France

3

Centre Hospitalier Dunkerque

Dunkirk, France

4

CHRU, Hôpital Claude Huriez

Lille, France, 59037